NeisVac-C


(not currently used in the UK’s Routine Childhood Immunisation Schedule) Manufacturer: Baxter Generic name: Meningococcal Group C Polysaccharide Conjugate Vaccine Adsorbed NeisVac-C Safety The vaccine was tested, as has become common practice, in trials that administered other vaccines at the same time. Mostly they studied how likely “solicited” events were to occur, which means that it was decided beforehand, which minor side-effects to look out for and record. [1] As a consequence, other side-effects can go unreported. In addition, the manufacturer of the trial vaccine will be able to say that there was no evidence that their vaccine was to blame for any of the side-effects, rather than one of the other vaccines administered at the same time. It was already unsatisfactory when vaccine safety trials were done without a real placebo group, where the control group was another vaccine. Now the trials have become even more meaningless. The list further below contains the adverse reactions which were found and published. Like many vaccines, NeisVac-C contains aluminium hydroxide, a widely-used adjuvant in vaccines. Previous mercury-containing adjuvants are now less common and it is hoped that those based on aluminium are safer. But due to the lack of long-term studies, we have to rely on passive reporting of vaccine adverse reactions, which usually tell us very little about the real risk. Whether or not the new adjuvants are safe is questionable. They are both strongly attacked and strongly defended. Safety levels are arbitrary and the effect on infants and their developing bodies (especially neurologically) is unknown. The MHRA, the UK’s regulator, recorded over 14,000 adverse events and 37 deaths since 1999 from vaccines of this kind. The MHRA data only shows that someone believed the vaccine to be responsible for a certain side-effect. It doesn’t prove that the vaccine was responsible,…

This content is for VIP members only.
Log In Register